Applying Fibroscan which is superior to other NAFLD detective devices like sonography in regard to accuracy, enrolling subjects recently diagnosed with NAFLD prior to prescribing with strict therapies, using the varied types of soy isoflavones rather than one type, and measuring the level of FGF-21 and fetuin A as new hepatokines to predict the advancement of NAFLD are some strengths related to the present study. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.